A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.
The Omicron variant of SARS-CoV-2 initially detected in South Africa in November 2021 during the ongoing coronavirus disease 2019 (COVID-19) pandemic, spread around the world at a ferocious pace, and is known to carry more than 30 mutations in its spike glycoprotein.
Moreover, the Omicron variant has been linked to a rather rapid increase in case numbers, with recent data demonstrating substantial re-infection rates and vaccine ‘breakthrough’ potential, probably due to a successful evasion of neutralizing antibody responses.
On the other hand, recent findings suggest (somewhat paradoxically) that there is also a reduced disease severity in individuals infected with the Omicron variant when compared to the Delta variant of concern. The pertinent question then is – does that mean SARS-CoV-2 is evolving into a milder virus?
In this Nature paper, the large international research group explored biological properties of Omicron variant of concern with particular focus on spike-mediated evasion of neutralizing antibodies, increased receptor binding affinity, as well as a shift in tropism away from cells expressing TMPRSS2 and reduced ability to generate syncytia (or fused cells).
Appraising neutralization and cell entry
One of the critical questions in this study was whether antibodies developed after vaccinations are able to neutralize Omicron. For that purpose, the researchers have synthesized codon-optimized spike expression plasmids for spike glycoproteins for both Delta and Omicron variants of concern.
Then they have generated pseudovirus particles by co-transfecting the spike expression plasmids with a lentivirus, which represents an efficient method for the delivery of transgenes for research purposes. Many different cell lines were used to explore the propensity for cell entry, as well as the action of certain drugs.
In order to confirm the loss of neutralizing activity against the Omicron variant following the second vaccine dose, the researchers have used a live virus experimental system for comparing Delta and Omicron variants against serum specimens taken four weeks after the second dose of BioNTech/Pfizer (BNT162b2) vaccine.
Lower affinity for the cell receptor
The study has highlighted that spike glycoprotein in Omicron SARS-CoV-2 variant comes with a higher affinity for angiotensin-converting enzyme 2 (ACE2) cell receptor (which is pivotal for cell entry) in comparison to the Delta variant of concern.
Furthermore, there is a marked change of antigenicity due to a cornucopia of mutations, which results in significant evasion of monoclonal antibodies used for treatment, but also vaccine-elicited polyclonal neutralizing antibodies after two doses. Still, mRNA vaccination as a third vaccine dose in a way rescues and broadens this neutralization process.
The defect for Omicron pseudovirus to enter specific cell types in an effective manner has been correlated with higher cellular RNA expression of TMPRSS2 (Transmembrane Serine Protease 2), while a knock-down of TMPRSS2 influenced Delta entry to a much greater extent than Omicron.
More specifically, the replication process was similar for Omicron and Delta variants in human nasal epithelial cultures; however, in lower airway organoids, lung cells, and intestinal cells, Omicron showed much lower replication potential.
Drug inhibitors that target specific entry pathways demonstrated that the Omicron spike glycoprotein does not efficiently utilize TMPRSS2 protease, which actually promotes cell entry via plasma membrane fusion. This means this variant depends more on cell entry via the endocytic pathway.
The need for complex molecular insights
In summary, the Omicron SARS-CoV-2 variant has gained immune evasion properties, but at the same time compromised cell entry in TMPRSS2 expressing cells (primarily those in alveoli), as well as the ability to form syncytia or cell fusion – a combination characteristically linked to reduced ability to cause a severe disease.
“Our data showing tropism differences for Omicron in organoid systems and human nasal epithelial cultures are limited by the fact that they are in vitro systems, albeit using primary human tissue”, state study authors in this Nature paper.
“It should also be noted that levels of TMPRRS2 may impact ACE2, particularly as TMPRSS2 has been implicated in ACE2 cleavage, and our effect sizes were impacted by ACE2 expression”, they emphasize.
Most importantly, the experience with the Omicron variant has clearly shown that any predictions regarding replication and tropism based only on gene sequence can be misleading; thus, a comprehensive molecular understanding of the tropism change will be pivotal as novel SARS-CoV-2 variants continue to emerge.
News
Scientists Unlock a New Way to Hear the Brain’s Hidden Language
Scientists can finally hear the brain’s quietest messages—unlocking the hidden code behind how neurons think, decide, and remember. Scientists have created a new protein that can capture the incoming chemical signals received by brain [...]
Does being infected or vaccinated first influence COVID-19 immunity?
A new study analyzing the immune response to COVID-19 in a Catalan cohort of health workers sheds light on an important question: does it matter whether a person was first infected or first vaccinated? [...]
We May Never Know if AI Is Conscious, Says Cambridge Philosopher
As claims about conscious AI grow louder, a Cambridge philosopher argues that we lack the evidence to know whether machines can truly be conscious, let alone morally significant. A philosopher at the University of [...]
AI Helped Scientists Stop a Virus With One Tiny Change
Using AI, researchers identified one tiny molecular interaction that viruses need to infect cells. Disrupting it stopped the virus before infection could begin. Washington State University scientists have uncovered a method to interfere with a key [...]
Deadly Hospital Fungus May Finally Have a Weakness
A deadly, drug-resistant hospital fungus may finally have a weakness—and scientists think they’ve found it. Researchers have identified a genetic process that could open the door to new treatments for a dangerous fungal infection [...]
Fever-Proof Bird Flu Variant Could Fuel the Next Pandemic
Bird flu viruses present a significant risk to humans because they can continue replicating at temperatures higher than a typical fever. Fever is one of the body’s main tools for slowing or stopping viral [...]
What could the future of nanoscience look like?
Society has a lot to thank for nanoscience. From improved health monitoring to reducing the size of electronics, scientists’ ability to delve deeper and better understand chemistry at the nanoscale has opened up numerous [...]
Scientists Melt Cancer’s Hidden “Power Hubs” and Stop Tumor Growth
Researchers discovered that in a rare kidney cancer, RNA builds droplet-like hubs that act as growth control centers inside tumor cells. By engineering a molecular switch to dissolve these hubs, they were able to halt cancer [...]
Platelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness. Scientists have found a way to improve the performance of brain-computer interface (BCI) electrodes by delivering anti-inflammatory drugs directly [...]
After 150 years, a new chapter in cancer therapy is finally beginning
For decades, researchers have been looking for ways to destroy cancer cells in a targeted manner without further weakening the body. But for many patients whose immune system is severely impaired by chemotherapy or radiation, [...]
Older chemical libraries show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, University of California San Diego scientists and an international team of [...]
Lower doses of immunotherapy for skin cancer give better results, study suggests
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National [...]
Researchers highlight five pathways through which microplastics can harm the brain
Microplastics could be fueling neurodegenerative diseases like Alzheimer's and Parkinson's, with a new study highlighting five ways microplastics can trigger inflammation and damage in the brain. More than 57 million people live with dementia, [...]
Tiny Metal Nanodots Obliterate Cancer Cells While Largely Sparing Healthy Tissue
Scientists have developed tiny metal-oxide particles that push cancer cells past their stress limits while sparing healthy tissue. An international team led by RMIT University has developed tiny particles called nanodots, crafted from a metallic compound, [...]
Gold Nanoclusters Could Supercharge Quantum Computers
Researchers found that gold “super atoms” can behave like the atoms in top-tier quantum systems—only far easier to scale. These tiny clusters can be customized at the molecular level, offering a powerful, tunable foundation [...]
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
WASHINGTON -- A single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer, researchers reported Wednesday. HPV, or human papillomavirus, is very common and spread [...]
